Cohance Lifesciences share news and announcements
NSE: COHANCEBSE: 543064Pharmaceuticals & BiotechnologySmall Cap
Formerly Suven Pharmaceuticals
Last close ₹449.85down ₹4.00 (0.88%)BSE ₹448.65
Share price at the NSE close on 23 Oct 2026. Previous close ₹453.85.
52-week range of traded prices to 23 Oct 2026
₹266.70Low, 9 Mar 2026₹903.40High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹17,211 Cr428th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 162.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 134.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 4.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 4.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,73,70251.1% delivered
Cohance Lifesciences share news and announcements
373 announcements, routine notices left out, newest first. Page 4 of 8.
Dec 2024
7 Dec · Analysts
7 Dec · General Updates
7 Dec · Board meeting
2 Dec · Analysts
1 Dec · Analysts
Nov 2024
29 Nov · Rating
19 Nov · Analysts
18 Nov · Meeting
7 Nov · Analysts
6 Nov · Analysts
Oct 2024
25 Oct · Updates
22 Oct · Updates
Sep 2024
27 Sep · Board meeting
Meeting on 12 Nov 2024: “SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yea”23 Sep · Analysts
19 Sep · Management
13 Sep · Analysts
6 Sep · Analysts
5 Sep · Rating
Aug 2024
29 Aug · Analysts
14 Aug · Analysts
9 Aug · Board meeting
2 Aug · Analysts
Jul 2024
25 Jul · Updates
12 Jul · Updates
12 Jul · Board meeting
Jun 2024
13 Jun · Analysts
13 Jun · Business